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The BRCT domain is a highly conserved module found in many proteins that participate in DNA damage
checkpoint regulation, DNA repair, and cell cycle control. Here we describe the cloning, characterization, and
targeted mutagenesis of Brctx, a novel gene with a BRCT motif. Brctx was found to be expressed ubiquitously
in adult tissues and during development, with the highest levels found in testis. Brctx-deficient mice develop
normally, show no pathological abnormalities, and are fertile. BRCTx binds to the C terminus of hRAD18 in
yeast two-hybrid and immunoprecipitation assays and colocalizes with this protein in the nucleus. Despite this,
Brctx-deficient murine embryonic fibroblasts (MEFs) do not show overt sensitivity to DNA-damaging agents.
MEFs from Brctx-deficient embryos grow at a similar rate to wild-type MEF CD4/CD8 expressions, and the cell
cycle parameters of thymocytes from wild-type and Brctx knockout animals are indistinguishable. Intriguingly,
the BRCT domain of BRCTx is responsible for mediating its localization to the nucleus and centrosome in
interphase cells. We conclude that, although highly conserved, Brctx is not essential for the above-mentioned
processes and may be redundant.
The carboxyl-terminal domain (BRCT) of breast cancer
gene 1 (BRCA1) is the signature domain for a number of DNA
damage and checkpoint genes conserved throughout evolution
(4). There are 23 genes containing BRCT domains in the
human genome (www.ensembl.org). Proteins with BRCT do-
mains function as regulators of DNA repair, the cell cycle, and
transcription (4, 29). Much interest has surrounded these pro-
teins after the cloning of the breast and ovarian cancer suscep-
tibility genes BRCA1 and BRCA2 (18, 38). These genes have
subsequently been shown to play an important role in tumor
formation in other tissues (21, 35). Other proteins with BRCT
motifs include NBS1 and p53BP1, which have both been shown
to play a role in DNA repair. Mice carrying modified alleles of
NBS1 and p53BP1 are tumor prone (12, 37). It has recently
been shown that BRCT domains preferentially bind phos-
phopeptides in preference to unphosphorylated peptide frag-
ments (16, 40) and in doing so can transduce signals from
protein kinases operating in a variety of different signaling
cascades. Thus, the physiological targets of BRCT domain
proteins can be many and varied. Knockouts of BRCT domain
proteins have exhibited a variety of phenotypes such as embry-
onic lethality, growth defects, defects in T-cell development,
and infertility (8, 12, 20, 28, 36, 37). Thus, these proteins
exhibit a variety of functions during development.
In the present study we set out to investigate the function of
Brctx, an uncharacterized member of the BRCT domain-con-
taining family of proteins. The human homologue of Brctx is
located on chromosome 5q15, a region of the genome fre-
quently rearranged in cancers of the breast (10), bladder (27),
ovary (33), and lung (17); the tumor suppressor gene at this
locus has not been identified. Here we use expression profiling,
protein interaction, and targeted mutagenesis of Brctx to gain
clues about its function.
MATERIALS AND METHODS
Cloning of Brctx. BRCTx was identified in a database search for novel BRCT
domain proteins that localize to regions of frequent rearrangement in cancer
(www.ensembl.org) (3). We isolated Brctx from whole mouse brain cDNA by
reverse transcription-PCR (RT-PCR) with the primers 5-AAA AAA GAA TTC
ATG GAA GAT AGT GCC ACA AAA C-3 and 5-AAA AAA GGA TCC
CCC TGA AAC ATT TTT ACT AAG-3, with PCR Supermix High Fidelity
(Invitrogen, San Diego, Calif.), using 30 cycles of 20 s at 94°C, 1 min at 63°C, and
2 min at 68°C. This transcript was cloned into pBS (Stratagene, Palo Alto,
Calif.) and sequenced in full at the Australian Genome Research Facility. The
full sequence of the Brctx transcript used in our study has been given the
GenBank accession number AK012253.
Expression profiling of Brctx. Northern blotting was performed on mouse
tissue Northern blots containing whole RNA with the full-length Brctx cDNA as
a probe. RT-PCR was performed on a mouse rapid scan panel (Origene Tech-
nologies) with the primers Akexon1-2A (5-GGA AGA TAG TGC CAC AAA
ACA TAT CAT CC-3) and Akexon1-2B (5-TGC TGC ACA AGC TGC TAA
AAA CTT CTC-3) spanning exons 1 and 2 of Brctx and -actin primers (pro-
vided by the manufacturer). These reactions were performed with 50 l of PCR
Supermix (Invitrogen). For Brctx, 35 cycles of 20 s at 94°C, 1 min at 63°C, and 1
min at 72°C were performed. -actin amplification was performed using 37 cycles
of 20 s at 94°C, 1 min at 53°C, and 1 min at 72°C. Primer pairs were designed to
flank introns to ensure that there was no amplification of genomic contaminants.
The entire reaction was resolved in a 2% agarose gel in 1 Tris-acetate-EDTA
(TAE). mRNA in situ hybridization for Brctx expression was performed with an
automated Ventana Discovery instrument (Ventana Medical Instruments, Tuc-
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son, Ariz.) according to the manufacturer’s instructions. Briefly, tissues were
fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS). After 24 h
they were washed with PBS and dehydrated through a methanol series. Tissues
were then embedded in paraffin and 8-m sections were cut. These sections were
deparaffinized, fixed, acid treated, and then protease treated before being hy-
bridized with a digoxigenin-labeled antisense probe (50 ng/slide) for 6 h. The
signal was detected with an antidigoxigenin primary antibody (Jackson Immu-
noresearch Laboratories, West Grove, Pa.), followed by streptavidin-conjugated
alkaline phosphatase secondary antibodies and finally by incubation with ni-
troblue tetrazolium chloride–5-bromo-4-chloro-3-indolylphosphate toluidine salt
substrate solution for 6 h on the instrument. Sections were then counterstained
with neutral red. The antisense Brctx probe (full-length cDNA) was transcribed
from an EcoRI-linearized pBS plasmid by using T7 polymerase. An antibody to
human BRCTx (peptide; GFKMEEKEALVKLLLK) was raised in rabbits (Al-
pha Diagnostics, San Antonio, Tex).
Subcellular localization and confocal microscopy. For BRCTx localization
studies, the full-length Brctx cDNA was fused to enhanced green fluorescent
protein (EGFP) in pEGFP-C2 (Clontech, Palo Alto, Calif.) to make BRCTx-
EGFP. A deletion mutant containing the first 100 amino acids (100BRCTx-
EGFP) of BRCTx was generated by PCR with the reverse primer 5-AAA AAA
AAA AGG ATC CCT AAT AAT GGG AGT CTT TTT CAA TTT TAT ATC
CCC-3 in combination with the forward primer 5-AAA AAA AAA AAA GCT
TGA TGG AAG ATA GTG CCA CAA AAC ATA TCA TC-3. Reactions were
performed with PCR Supermix High Fidelity as described for the cloning of the
full-length Brctx. These products were cloned in frame in pEGFP-C2 and con-
firmed by sequencing. HeLa cells or 293HEK cells were cultured in Dulbecco
modified Eagle medium with 10% fetal calf serum (Invitrogen) on poly-L-lysine-
coated chamber slides (BD Biosciences, Palo Alto, Calif.). Transfections were
carried out by using Superfect (Qiagen, Germantown, Md.) or Lipofectamine
(Invitrogen) according to the manufacturer’s instructions. After 24 h, the cells
were fixed with methanol at 20°C and stained. Pericentrin and -tubulin stain-
ing was performed with antibodies PRB-432C from Covance (Dever, Pa.) and
GTU-88 from Sigma (Dorset, United Kingdom), respectively. Imaging was per-
formed by using a Bio-Rad scanning confocal microscope or a Zeiss Axioplan 2
imaging microscope with an Axiocam HRm camera. Images were imported into
Adobe Photoshop 6.0 and adjusted to use the full range of pixel intensities. For
colocalization of hRAD18 and BRCTx, a Flag-tagged hRAD18 cDNA (22) was
used with the full-length BRCTx-EGFP fusion construct as described above.
FIG. 1. BRCTx is highly conserved and ubiquitously expressed.
(A) Alignment of BRCTx homologues and splice variants from human
mouse and rat reveals a high level of conservation. This alignment was
generated by using contiguous cDNA sequences rather than assembled
cDNAs. The BRCT domain is underlined in red. (B) Human BRCTx
is a protein of ca. 36 kDa. (C) Northern blotting of mouse RNA illus-
trates strong expression of Brctx in the testis. (D) RT-PCR expression
profiling of Brctx shows ubiquitous expression. -actin is the internal
control.
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Flag-hRAD18 fusion proteins were detected by using M2 monoclonal antibody
from Sigma.
Response of BRCTx-EGFP fusion proteins to DNA damage in V79 cells. A
hamster V79 cell line stably expressing a BRCTx-EGFP fusion protein was
generated by transfection of the full-length BRCTx-EGFP construct (described
previously), and selection for stable integrants in G418 (Invitrogen). Appropriate
expression of the chimeric protein was confirmed by Western blotting (data not
shown). Relocalization experiments were performed as described previously (6).
Cell lines stably expressing RAD51-EGFP were used as a control in all experi-
ments (6) (data not shown).
Yeast two-hybrid analysis and coimmunoprecipitation. The budding yeast
Saccharomyces cerevisiae AH109 (11) was cultured in YPAD (1% [wt/vol] yeast
extract, 2% [wt/vol] peptone, 0.003% [wt/vol] adenine, 2% [wt/vol] dextrose) and
transformed with the plasmid pGBKT7-Brctx containing the full-length Brctx
cDNA. Activation domain plasmids, in pAct2 (Clontech), were transformed into
Y187 (9). AH109 and Y187 were mated and selection performed on semisolid
synthetic defined medium supplemented with kanamycin (30 g/ml) for 1 week
at 30°C (1, 2). Transformants were then transferred onto membranes for assess-
ment of -galactosidase expression by a filter assay (34). An hRAD18 cDNA was
isolated by screening a pretransformed pAct/Y187 fetal brain cDNA library
containing 2  106 independent cDNA clones (Clontech). Coimmunopre-
cipitations were performed with Flag-tagged hRAD18 cDNA or hRAD18 de-
letion mutants (22) and the full-length tagged Brctx-EGFP plasmid in 293T
cells.
Generation of Brctx-deficient mice. The Brctx targeting vector was constructed
by using the PGK-neoF2L2DTA backbone (kindly provided by Phil Soriano,
Fred Hutchinson Cancer Research Center, Seattle, Wash.). Vector arms were
amplified from the PAC clone RP21-371G10, derived from 129S6/SvEvTac
mouse DNA (24). Reactions were performed in 50 l of PCR Supermix High
Fidelity with 15 cycles of 20 s at 94°C, 1 min at 63°C, and 6 min at 68°C. The 5
arm of the vector was amplified with the primers 5-AAA AAA AAG CGG CCG
CAA TAC ATT CAA ATG CTT TAA CAA TTT ATA CCT CAA AAC-3 and
FIG. 2. BRCTx localizes mainly to the nucleus and in some cells to the centrosome. (A) BRCTx fusions are appropriately expressed as
illustrated by this Western blot. (B) BRCTx-EGFP fusion proteins localize to the nucleus and in some cells (10 to 15%) colocalizes with -tubulin
and pericentrin, which are centrosomal proteins. Some scant staining of BRCTx-EGFP was observed in the cytoplasm. (C) The BRCT domain of
BRCTx (100BRCTx-EGFP) mediates the localization of this protein to the centrosome (arrow).
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5-AAA AAA AAG CGG CCG CCT AAC AGC TGG CCA AAA AGG CGA
GCT CCA TAC AGA AGA TAG CAG ATG TTA AAC ATT ATG C-3 and
cloned into the NotI site of the vector. The 3 arm of the targeting vector was
amplified by using 5-AAA AAA AAG CTT CAC GCT TCC TCA CCA CTG
AGA CAC CCA GAG CAA AC-3 and 5-AAA AAA AAG CTT TCT GAT
CTA ACG AAG AAG CAA CAT AAT CTA TAG GAC-3. This fragment was
cloned by using XbaI and XhoI into the NheI and SalI sites of PGK-
NeoF2L2DTA. Then, 25 g of SacII-linearized DNA was electroporated into
AB2.2, 129S7 embryonic stem cells. Confirmation of targeting and genotyping
was performed by Southern blotting on BglI-digested genomic DNA with a 5
probe amplified by using the primers 5-GTA TGT TCT GAA GTA TGG AGG
ACT GAG-3 and 5-TCT TCA AAC ATG TGC CAG TAC TGG C-3 and a 3
probe amplified by using the primers 5-CAC TTT TAG CTT CTG AAC ATC
TCT CAC TCC C-3 and 5-TAT GTG GGT GGA CAT GCA AGC AAG
CAC-3. Blastocyst and chimeric mice were produced as described previously
(26). All experiments were performed with mice on a mixed 129S7/SvEvBrd and
C57BL/6J-Tyrc-Brd background. Mice were housed in accordance with Home
Office regulations (United Kingdom).
Micronuclei assay, T-cell analysis, and thymocyte cell cycle studies. For the
micronucleus assay blood was collected from adult mice (6 to 8 weeks old) by
cardiac puncture during terminal anesthesia and immediately fixed in 80°C
methanol overnight. DNA, CD71 antibody staining, and fluorescence-activated
cell sorting (FACS) analyses were performed with reagents from Litron Labo-
ratories (Rochester, N.Y.). A total of 50,000 red cells from each animal were
examined. For analysis of T cells, whole spleens and thymuses were prepared as
described previously (15, 31) and stained with CD4-propidium iodide (PI)
and CD8-fluorescein isothiocyanate (FITC) antibodies purchased from
Pharmingen (Palo Alto, Calif.). Then, 10,000 cells were examined from each
organ by FACS. For cell cycle analysis, thymuses were collected from adult
(6- to 8-week-old) Brctx-null and wild-type animals, treated with RNase A,
and labeled with PI (7). All FACS data analysis was performed by using
WinMDI 2.8 software.
Histology and organ analysis. Tissues were collected and fixed in 10% neutral
buffered formalin, processed, and stained with hematoxylin and eosin by using
standard methods (19). Organ weights were recorded from between four to six
animals of each sex at 8 weeks of age.
DNA repair and cell growth assays. Mouse embryonic fibroblasts (MEFs)
were prepared as described previously (23, 28) from embryonic day 13.5 em-
bryos. DNA repair and cell growth assays were performed on exponentially
growing MEFs between passages two and five. Cells were seeded into gelatinized
96-well plates at a density of 4,000 cells/well the day before treatment. However,
ionizing radiation (IR) treatment was performed on cells in suspension prior to
plating. UV was delivered by using 254 nm, 40-W/m2 germicidal bulbs. Methyl
methanesulfonate (MMS) was delivered to cells in warmed medium for 1 h and
then washed off with warmed medium. Controls were treated with dimethyl
sulfoxide, which is the vehicle for MMS. Mitomycin C (MMC) was dissolved in
medium, and cells were fed daily at various doses. MMS and MMC were pur-
chased from Sigma. MTT assays were performed on cells 5 days after treatment
with CellTiter reagent (Promega, Madison, Wis.) according to the manufactur-
er’s recommendations. A minimum of 12 wells were analyzed and averaged for
each data point at each dose from three independent experiments for MMC and
IR and five experiments for MMS and UV. For cell growth assays, MEFs were
seeded at a density of 1.5  106/10-cm plate at day 0. Cells were counted daily
using a Coulter counter (Beckman Coulter, Fullerton, Calif.). The data were
collected from duplicate cell counts from three independent experiments.
RESULTS
BRCTx is a conserved, ubiquitously expressed, centrosomal
protein. The amino acid sequence of BRCTx homologues from
human, mouse, and rat sources show a high level of conserva-
tion (Fig. 1A). This conservation is particularly marked in the
N terminus of the protein containing the BRCT domain. The
alignment shown in Fig. 1A was compiled from protein se-
quences predicted from contiguous DNA fragments containing
a start and stop codon and, where available, the splice variants
are indicated. Several database entries for related predicted
proteins, which were derived from assembled cDNAs, suggest
that BRCTx is a much larger protein of between 700 and 900
amino acids. These predictions are inconsistent with our West-
ern blot results, which show that BRCTx is a protein of ca.
36 kDa in human HCC1143 breast carcinoma cells (Fig. 1B).
Northern blotting illustrates that Brctx is expressed at high
levels in mouse testis (Fig. 1C). By RT-PCR we illustrate
that Brctx is in fact expressed ubiquitously in all tissues and
throughout the developing embryo (Fig. 1D). This corre-
lates with expressed sequence tag data (www.ncbi.nlm.nih
.gov/unigene/), which suggests a broad pattern of expres-
sion.
To reveal the subcellular localization of BRCTx, we tagged
the N terminus of the full-length Brctx cDNA with EGFP. This
revealed that BRCTx is localized mainly to the nucleus with
scant expression in the cytoplasm, Fig. 2. Double labeling of
cells with either -tubulin or pericentrin, which are markers of
the centrosome, and BRCTx shows that these proteins colo-
calize in ca. 10 to 15% of cells (Fig. 2). To determine the
domain of the protein controlling localization, we generated a
truncation mutant (100BRCTx-EGFP) of BRCTx containing
the first 100 amino acids (BRCT domain) of the protein. This
truncation mutant colocalized with -tubulin (Fig. 2), in some
cells, suggesting that the BRCT domain of BRCTx is respon-
sible for its centrosomal localization. In situ hybridization for
Brctx in mouse testis revealed that it is mainly expressed in
spermatocytes (Fig. 3). Sections were also hybridized with
probes against Gli-1, which mainly stains germ cells and a
subset of pachytene spermatocytes, and SSh, which does not
stain the testis.
BRCTx interacts and colocalizes with the post-replication-
repair protein hRAD18. We performed a yeast two-hybrid
FIG. 3. In situ hybridization for Brctx in adult testis. In situ hybrid-
ization revealed expression of Brctx in spermatocytes. (Inset) High-
power view of testis section showing blue cytoplasmic RNA staining.
Expression of Gli-1 which stains spermatocytes and germ cells, and Shh
which does not stain the testis, was also assessed. BRCTx/ refers to
tissue from a Brctx knockout animal.
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FIG. 4. BRCTx binds to hRAD18 in yeast two-hybrid and immu-
noprecipitation assays, and these proteins colocalize in the nucleus.
(A) Screening of a fetal brain cDNA library isolated a cDNA clone of
hRAD18. This interaction was confirmed by growth on selective me-
dium (i) and by the LacZ assay (ii). (B) The interaction between
BRCTx and hRAD18 was confirmed by coimmunoprecipitation. Com-
plexes were precipitated with Flag antibodies on agarose beads. A
specific product of the correct size was observed in three independent
experiments. hRAD18 does not interact with the N-terminal BRCT
domain (100BRCTx-EGFP). Flag-BAP (bacterial alkaline phospha-
tase) was used as a negative control. (C) Structure of hRAD18 deletion
mutants. (D) BRCTx interacts with the hRAD18 Flag D-SAP and Flag
D-Zinc fusion proteins. (E) BRCTx and hRAD18 colocalize in the
nucleus. Both proteins appeared to localize to the centrosome in some
cells but in the majority of cases are distributed evenly throughout the
nucleus. Arrow indicates centrosomes.
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screen to isolate proteins that interact with BRCTx. We iden-
tified a full-length cDNA encoding the post-replication-repair
protein hRAD18 (32) (Fig. 4A). This cDNA was found to be in
frame with the Gal4 activation domain. We confirmed this
interaction by growth on selective medium, by LacZ assay, and
by coimmunoprecipitation in 293T cells (Fig. 4A and B). We
reveal that the C terminus of BRCTx is critical for the inter-
action (Fig. 4B). This domain does not contain any known
protein interaction motifs. Further analysis revealed that res-
idues in the C terminus of hRAD18, between amino acids
285 and 495, mediate its interaction with BRCTx (Fig. 4D).
Thus, the well-characterized ring, zinc (Zn), and SAP do-
mains do not appear to participate in the interaction be-
tween these proteins. The C-terminal end of hRAD18 was
recently shown to be important for its interaction with pol
and was implicated in recruiting pol to sites of DNA dam-
age by protein-protein interaction and by PCNA monoubiq-
uitination (39).
We also show that BRCTx colocalizes with hRAD18 in the
nucleus (Fig. 4E). Strong interactions between BRCTx and
HDAC2, RAN-BPM, and TACC2 were also observed in our
yeast two-hybrid screen (data not shown), but these interac-
tions could not be confirmed by coimmunoprecipitation from
293T cells.
Targeted disruption of Brctx. We knocked out Brctx in em-
bryonic stem cells by using a vector designed to delete the first
two coding exons (Fig. 5A). Homozygous null animals were
obtained at expected Mendelian ratios from interbreeding
Brctx heterozygotes (Fig. 5B). Test matings revealed that both
Brctx-null males and females were fertile. Disruption of
the gene was confirmed by RT-PCR performed on testis
cDNA (Fig. 5C) and by in situ hybridization on testis sec-
tions (Fig. 3). RT-PCR revealed that Brctx transcripts were
produced from the mutant allele but these were fusions
between the 5 untranslated region (UTR; exon 1) and exon
5. This mutant mRNA transcript does not produce a trun-
cated form of BRCTx because it lacks an in-frame start
codons.
Assessment of T-cell compartment and body and organ
weights. Given that knockouts of other proteins with BRCT
FIG. 5. Targeted disruption of Brctx in mice. (A) Brctx was disrupted by recombination of a PGK-neo cassette with the first two coding exons
resulting in disruption of the BRCT domain. (B) Diagnostic Southern blotting performed on mouse tail DNA by using external probes 5 and 3
of the targeting vector. (C) RT-PCR performed on testis cDNA from wild-type WT (/) and Brctx-null (/) animals revealed that/ animals
had a truncated Brctx transcript formed by the fusion of the 5UTR (exon 1) with exon 5. This transcript lacks in-frame start codons for BRCTx.
-actin and ethidium bromide were used as internal controls for RNA quality.
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domains show severe defects in T-cell maturation, growth
impairment, and abnormal spleen and thymus weights (20),
we investigated these parameters in Brctx-null mice. Body
weight, and the weights of spleens and thymuses from 6- to
8-week-old Brctx-null and wild-type animals were similar
(Fig. 6A and B). Histopathologic analysis of spleens re-
vealed a slight increase in extramedullary hematopoiesis in
Brctx-null animals, which may account for their slightly larg-
er size compared to wild-type spleens. Additional histo-
pathologic analysis on Brctx-null tissues from all other organ
systems revealed no major defects compared to tissues from
littermate controls. No significant differences in the CD4/
CD8 profiles of spleens and thymuses from wild-type and
knockout animals (Fig. 6C) was observed. The cell cycle pro-
files of thymuses from Brctx-null and wild-type animals were
comparable (Fig. 6D).
Assessment of the role of Brctx in DNA repair. We used the
flow cytometric micronucleus assay to determine whether
FIG. 6. Analysis of thymic and splenic T-lymphocytes and of organ and body weights in Brctx-null and wild-type animals. Body (A) and organ
(B) weights from Brctx-null and wild-type animals are indicated. Adult animals, 6 to 8 weeks of age, were weighed at necropsy when organs were
collected. T, thymus; S, spleen. The data are presented as means 	 standard deviations. (C) Spleens and thymuses were taken from adult animals
and stained with CD4-PI and CD8-FITC. A minimum of 10,000 events were analyzed from each organ. The data are presented as means 	 the
standard deviations. (D) PI cell cycle of thymocytes.
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Brctx-null mice exhibit an overt DNA repair defect or have
unstable genomes (Fig. 7). These data showed that Brctx-null
animals were indistinguishable from their wild-type litter-
mates.
Assays for DNA repair, growth, and cell cycle analysis of
Brctx-null cells. We observed no significant differences in the
growth of Brctx-null cells compared to wild-type cells (Fig. 8A).
The sensitivity of Brctx-null MEFs to DNA-damaging
agents was examined (Fig. 8B). These assays revealed that
Brctx-null MEFs are not overtly sensitive to any of the tested
mutagens, although they did appear to show marginal sen-
sitivity to UV irradiation. We also investigated the response
of BRCTx-EGFP fusion proteins to UV irradiation and IR
(Fig. 8C). BRCTx-EGFP fusions did not relocalize in re-
sponse to DNA damage, unlike RAD51-EGFP fusion pro-
teins, which were used as a control (data not shown).
DISCUSSION
We show here that BRCTx is a highly conserved, hRAD18
interacting protein that is dispensable for fertility and viability.
Although other hRAD18 interacting proteins have been re-
ported to participate in DNA repair (13), assays performed on
Brctx-null murine embryonic fibroblasts suggest that these cells
are not more sensitive to DNA-damaging agents than are wild-
type cells. In addition, we have been unable to detect any major
defects in embryonic development, in T-cell development, or
in the genomic stability of these mice. MEFs from Brctx-null
embryos appear to grow at a normal rate, and Brctx-null thy-
mocytes do not show any major cell cycle defects (Fig. 6). We
have had Brctx-null mice in our facility for at least 18 months.
These mice have failed to exhibit any of the characteristic signs
of premature aging, which have been attributed to other DNA
repair knockouts (5). Collectively, these observations and the
observation that Brctx is highly conserved in humans, mice, and
rats appears to be in conflict. One explanation may be that
Brctx is redundant. Although there are no Ensembl proteins
that show 
40% amino acid similarity to BRCTx, it is possible
that there are genes in the genome that encode proteins that
may compensate for the loss of Brctx. In an attempt to recon-
cile this discrepancy, we performed microarray analysis to look
for differences in the expression profile of Brctx-null MEFs
compared to wild-type MEFs (data not shown). These exper-
iments revealed only two genes, H19 (25) and CXCL12 (30), to
be
2-fold overexpressed in Brctx-null cells (P 0.05). Neither
of these genes have been implicated in DNA repair or the cell
cycle. Thus, it seems unlikely that these expression differences
are of functional significance.
At this stage it is not possible to determine whether Brctx
plays a role in tumorigenesis. It is interesting that chromosome
5q15, where BRCTX resides, has recently been shown to be a
hotspot for rearrangements in p53-negative tumors (10). It is
FIG. 7. Assessment of genomic instability. Micronucleus assays on blood from Brctx-null (/) and wild-type (/) animals were performed.
Peripheral blood was stained with CD71-FITC antibodies and with PI, which stains DNA. The data represent analyses of blood from five animals,
8 to 10 weeks of age, of each genotype (mean 	 the standard deviation). A minimum of 50,000 events was analyzed for each sample. Red cell
subcompartments are indicated. Results for reticulocytes (Ret), normochromatic erythrocytes (NCE), nucleated reticulocytes (MN-Ret),
and nucleated normochromatic erythrocytes (MN-NCE) are shown. Bloom (Blm)-deficient mice (14), were used as a positive control (data
not shown).
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compelling to speculate that there is some interaction between
BRCTX and p53, which may explain the rearrangement of 5q15
observed in tumor samples.
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